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Summary The MIB-l antibody has been raised against recombinant parts of the Ki-67 antigen and, unlike
Ki-67, has wider application to routinely fixed specimens. The aim of this study was to compare the usefulness
of MIB-l with S-phase fraction (SPF) as a measure of proliferation. A total of 75 patients with operable breast
cancer were studied, 44 (median age 56 years) before any treatment and 31 (median age 68 years) after primary
medical hormonal therapy. Sections from formalin-fixed paraffin-embedded tissue were stained with the MIB-1
antibody and a percentage score of positively stained cells obtained. SPF was measured by flow cytometry in
fine-needle aspiration samples taken from the same lesion in each patient. Median MIB-1 score was 9% and
median SPF was 1.1%. A close correlation was found between MIB-1 score and SPF (rho =0.59, P < 0.0001).
There was a difference in the strength of the correlation found between the no treatment group and the
treatment group, however, 95% confidence intervals for the rho values overlapped, indicating that there was no
significant statistical difference. When analysed for ploidy status a correlation was found only in aneuploid
tumours. MIB-l immunostaining can be used as an effective method of assessing proliferation in human breast
carcinomas. This can be done using simple, widely available technology and provides the opportunity to
perform large-scale retrospective analyses of archival material.
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The assessment of the proliferative activity of breast
carcinomas has been shown to be of prognostic significance
using a number of different methodologies. Several long-term
follow-up studies have demonstrated proliferative indices to
be predictive for relapse-free and overall survival using both
thymidine labelling index (TLI) (Tubiana et al., 1984;
Silvestrini et al., 1985) and DNA flow cytometric determina-
tion of S-phase fraction (SPF) (Stal et al., 1993; Wenger et
al., 1993; Camplejohn et al., 1994; Mansour et al., 1994). SPF
is considered by many to be the 'gold standard' for assessing
tumour proliferation and is a widely used prognostic factor in
some countries (Dressler et al., 1988; Wenger et al., 1993).
The immunohistochemical determination of proliferation
markers is an expanding area of research and use of the
monoclonal antibody Ki-67 is now widely accepted. This
antibody reacts with a nuclear antigen present in all cycling
cells (Gerdes et al., 1984). Ki-67 staining has been shown to
be an independent prognostic factor with respect to early
recurrence (Sahin et al., 1991; Wintzer et al., 1991; Veronese
et al., 1993), although follow-up renders conclusions about its
relationship to survival premature. A number of studies have
shown a significant correlation between Ki-67 staining and
SPF in breast cancer (Walker and Camplejohn, 1988; Isola et
al., 1990; Vielh et al., 1990; Gasparini et al., 1994), however
use of the Ki-67 antibody has methodological drawbacks, in
particular the restriction of its use to frozen tissue.
MIB-1 is a recently developed monoclonal antibody that
has been raised against recombinant parts of the Ki-67
antigen (Key et al., 1992). It has been shown to correlate
strongly with Ki-67 staining and has the advantage of
reacting with epitopes in routinely fixed, wax-embedded
specimens (Cattoretti et al., 1992), thereby providing staining
with improved preservation of tissue architecture and
allowing its usage in studies of archival material. MIB-1
staining has been compared with standard measures of
proliferation such as bromodeoxyuridine labelling in gliomas
(Onda et al., 1994) and SPF in lymphomas (Pich et al., 1994),
showing a strong and moderate linear correlation respec-
tively. To our knowledge no similar studies have been
performed in breast cancer.
We present here data comparing MIB-1 with SPF in 75
breast carcinomas and discuss its suitability as a measure of
proliferation in this tumour type.
Materials and methods
Patients
Tissue samples were collected from 75 post-menopausal
patients with operable breast cancer. Invasive carcinoma
was confirmed in all cases (73 infiltrating duct carcinomas
and two invasive lobular carcinomas). Forty-four patients
(median age 56 years) were studied before any treatment.
Thirty-one patients (median age 68 years) were studied
following short-term primary medical hormonal therapy.
Treatments were as follows: tamoxifen, 21 patients
(Johnston et al., 1993) (5-35 days, median 18 days); the
antiprogestin, onapristone (Michna et al., 1990), 12 patients
(14 days): and the aromatase inhibitor, 4-hydroxyandroste-
nedione (Coombes et al., 1984), two patients (14 days).
MIB-1 staining and scoring
Surgical excision specimens (70 patients) and core-cut
biopsies (five patients) were fixed in 4% formaldehyde in
saline and embedded in paraffin wax. Sections (3 ,um) were
dewaxed, rehydrated, brought to water, then placed in 300 ml
of citrate buffer and heated twice for 5 min each in a
microwave oven at 750 W and allowed to cool. After the
addition of normal rabbit serum the sections were incubated
with MIB-1 monoclonal antibody (Binding Site) at a 1: 50
dilution for 1 h. Slides were then incubated successively with
biotinylated rabbit anti-mouse antibody (DaKo), and the
avidin-biotinylated horseradish peroxidase complex (ABC;
DaKo) (Hsu et al., 1981) developed with diaminobenzidine
(DAB) (Sigma) and counterstained with haematoxylin. All
washes were with phosphate-buffered saline (PBS), and
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incubations were carried out at room temperature. A section
from a human tonsil was included as a positive control and a
breast carcinoma section with the MIB-1 antibody acted as a
negative control.
MIB-1 immunostaining was scored using a standard light
microscope (x 40 objective). Malignant cells with nuclear
staining of any intensity were regarded as positive. The
percentage of positively stained cells was determined in each
of ten high-power fields spread randomly through the section
and an average score obtained. At least 1000 cells were
counted in all samples.
DNA flow cytometry
Before surgical excision or core-cut biopsy, fine needle
aspiration biopsies were taken from the same lesion using a
23 gauge needle. A cell suspension was made in 2 ml of
minimal essential medium (Gibco) that was then snap frozen
in liquid nitrogen.
For flow cytometric analysis the frozen cell suspension was
thawed at 37°C, centrifuged at 1000 r.p.m. for 10 min and
the pellet resuspended in 200 ul of PBS containing 0.5 mM
EDTA, 0.5% Nonidet P-40 (Sigma), 20 ,ug ml-' propidium
iodide, 200 jig ml-1 RNAase (Sigma), pH 7.2 (Larsen, 1994).
The suspension was kept on ice for at least 30 min before
analysis.
The nuclei were analysed on an Ortho Cytofluorograf 50H
equipped with a Spectra Physics argon ion laser producing
200 mW at 488 nm and an Ortho 2150 computer system.
Forward and orthogonal light scatter, the peak and area of
the red fluorescence were recorded. After gating on a
cytogram of peak vs area of the red fluorescence to remove
debris and clumped nuclei from the analysis (Ormerod, 1994),
a cytogram of orthogonal vs forward light scatter was
displayed. By gating on light scatter DNA histograms
enriched either for tumour nuclei (high scatter) or normal
nuclei (low scatter) were produced. The histograms were
transferred to an IBM-compatible PC and further analysis
and production of diagrams was performed using software
written by one of the authors (MGO).
All the samples contained some normal cells (diploid, low
light scatter). The position of the GI peak from the DNA
histogram of the normal cells was compared with that of the
GI peak from the tumour and used to compute the DNA
index (DI) (tumour cell GI DNA content-normal
cell GI DNA content).
The percentage of cells in S-phase was estimated by
placing a region in the centre of the histogram, which
contains only cells in S-phase, and doubling the percentage
obtained. It was not possible to measure S-phase in polyploid
and hypodiploid (DI < 1.0) tumours or when the DNA was
badly degraded (coefficient of variation across the G, peak
> 10%).
Statistical analysis
Correlations between MIB-1 and SPF were analysed by
Spearman's rank coefficient and 95% confidence intervals
(95% CI) for rho values were calculated (Zar, 1984).
Comparisons between DNA aneuploid tumours and diploid
tumours for MIB-1 were made using the Mann-Whitney U-
test.
Results
MIB-1 staining was confined to the cell nucleus, the majority
of the sections were homogeneously stained and there was
little background staining. While the intensity of staining
varied from weak to very intense both within and between
tumours, positive nuclei were readily identifiable (Figure 1).
The overall median MIB-1 score was 9.0% (range 1-83.4%).
The median MIB-1 score in the no treatment group was 8.6%
(range 1.9-83.4%) and 9.6% (range 1-64.9%) in the
treatment group.
Figure 1 Immunohistochemical staining of breast carcinoma
with the MIB-1 antibody.
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Figure 2 Correlation between MIB-1 score and S-phase fraction
(SPF) determined by flow cytometric analysis (rho =0.59,
P<0.0001, n=75). 0, No treatment group (rho=0.54,
P<0.0001, n=44); 0, Treatment group (rho=0.071, P<0.0001,
n=31).
The mean coefficient of variation for the flow cytometry
analyses was 7.2+ 0.2 (s.e.m.). Of 75 tumours, 29 were
diploid and 46 were aneuploid. The overall median SPF was
11.1% (range 0.5-31.8%). The median SPFs in the treatment
and no treatment groups were virtually identical: 11.0%
(range 0.5-31.8%) and 11.1% (range 1.6-30.6%) respec-
tively.
Using Spearman's rank correlation analysis there was a
close relationship between MIB-1 score and SPF (rho=0.59,
95% CI 0.48-0.76, P <0.0001, Figure 2). The strength ofthis
correlation appeared to differ between the no treatment
group (rho=0.54, 95% CI 0.33-0.75, P<0.0001) and the
treatment group (rho=0.71, 95% CI 0.51-0.87, P<0.0001).
However, the overlapping 95% confidence intervals for the
rho values indicated that this difference was not significant.
The median MIB-1 score was significantly higher in the
DNA aneuploid tumours (11.6% n=46) than in the diploid
tumours (5.5%, n=29) (Mann-Whitney U-test P<0.004,
Figure 3). When the relationship between MIB-1 and SPF
was analysed according to ploidy status the previously noted
correlation was detected only in the aneuploid tumours
(rho =0.71, P<0.0001). No significant correlation was
detected in diploid tumours (rho = 0.26, P = 0.16) (Figure 4).
Discussion
The measurement of tumour proliferation is becoming
increasingly important in the field of breast cancer research.
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Figure 3 Comparison between MIB-1 scores in aneuploid and
diploid tumours. Median MIB-1 score is significantly higher in
aneuploid tumours compared with diploid tumours (11.6% vs
5.5%; Mann -Whitney U-test, P<0.004).
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Figure 4 Correlation between MIB-1 and SPF according to
ploidy status. *, Diploid tumours (rho=0.26, P=0.16, n=29);
0, aneuploid (rho=0.71, P<0.0001, n=46).
Not only has proliferative activity been shown to be a
prognostic indicator (Tubiana et al., 1984; Silvestrini et al.,
1985; Stal et al., 1993;Wenger et al., 1993; Camplejohn et al.,
1994; Mansour et al., 1994) but the ability to measure tumour
proliferation may be useful in other areas of investigation
such as inter-relationship of proliferation and apoptosis and
their effect on tumour growth rate, and the assessment of
pathological response to treatment. It is thus important to
have a technique that is accurate, reproducible and accessible
to most laboratories. The development of the monoclonal
antibody MIB-1 offers these possibilities. To evaluate the
reliability of MIB-1 as a measure of proliferation in breast
tumours we compared MIB-1 scores with an established cell
proliferation assay, DNA flow cytometric determination of
SPF.
Comparison of MIB-1 with SPF revealed a good
correlation between the two methods. In addition, this
correlation was maintained in those patients treated with
various endocrine agents. When analysed in relation to ploidy
status the correlation was only seen in the aneuploid
tumours, a finding also seen in studies comparing Ki-67
and SPF (Isola et al., 1990; Vielh et al., 1990). The fact that
MIB-1 scores were higher in aneuploid tumours in this study
is also in keeping with other studies suggesting similar results
for proliferation using SPF or Ki-67 (Isola et al., 1990;
Camplejohn et al., 1994).
There have been no previous studies comparing MIB-1
and SPF in breast cancer, however, Pinder et al. (1995) have
recently published a study measuring MIB-1 in 177 patients,
demonstrating a significant association with histological
grade and confirming tumour growth fraction using this
marker as an important predictor of survival. MIB-1 has
been shown to be correlated with established measures of
proliferation in other tumour types. Onda et al. (1994) found
a very close correlation between MIB-1 and bromodeoxyur-
idine labelling index in 90 cases of cerebral glioma (r=0.96),
while a study of 41 patients with malignant lymphoma
showed a correlation between MIB-l and SPF (r=0.51) (Pich
et al., 1994). A number of authors have looked at the
relationship between SPF and Ki-67 in human breast
tumours. Isola et al. (1990) found that Ki-67 correlated
with SPF in a study of 102 cases (r=0.51), while two other
studies of 96 cases (r=0.30) (Vielh et al., 1990), and 168 cases
(rho =0.38) (Gasparini et al., 1994) also found significant
correlations between these two methods. Given the fact that
MIB-1 is raised against recombinant parts of the Ki-67
antigen, a similar result would be expected for the correlation
of both these methods and SPF. Our results confirm this and,
along with the studies presented in other tumour types (Onda
et al., 1994; Pich et al., 1994), raise the suggestion that there
may be a slightly stronger correlation between MIB-1 and
SPF, compared with Ki-67 and SPF. A possible explanation
for this may be that antigenic preservation of Ki-67 protein is
better in formalin-fixed paraffin sections than in frozen
sections (Shi et al., 1991).
Although overall there was a correlation between MIB-1
and SPF, as with reported studies looking at Ki-67 and SPF
(Isola et al., 1990; Vielh et al., 1990) several different groups
of tumours were apparent. In the majority of cases there was
a close correlation between the two variables but with a
higher MIB-1 score compared with SPF. This is to be
expected and is explained by the fact that MIB-1 binds to a
nuclear antigen expressed during the GI, G2 and M phases of
the cell cycle, as well as in S-phase. In a significant
proportion of tumours, however, MIB-1 score was lower
than SPF, particularly those where MIB-1 was very low. It
has been shown that some tumour cells arrested in S-phase
are not recognised by the Ki-67 antibody (Van Dierendonck
et al., 1989; Vielh et al., 1990) and it is likely that this may
also apply to MIB-1. It is also possible that any error in
calculating the percentage of cells in S-phase may be
accentuated in tumours with very low proliferative activity,
leading to an overestimation of S-phase. This may explain the
apparent anomaly in our series of the median MIB-1 value
being slightly lower than the median S-phase value. Other
sampling errors may also lead to differences between these
two techniques. Tumour heterogeneity may mean that the
small samples taken are not necessarily representative of
proliferation throughout the whole tumour. Low cellularity
of the tumour may interfere with both types of analysis, as
can necrotic or poorly vascularised areas within a tumour.
In previous studies comparing MIB-1 or Ki-67 and SPF,
DNA flow cytometric analysis was performed on paraffin-
embedded tissues. A possible source of non-concordance in
this study is that the cell suspension from which SPF was
estimated was prepared from fine-needle aspiration biopsies
(FNABs). FNAB is a well-established method for diagnosing
breast lesions, and the specimens are well suited for flow
cytometry provided there are enough cells to complete the
steps required to achieve a single-cell suspension (Llung et al.,
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1994). We and others have now validated the application of
this technique in FNAB (Remvikos et al., 1988; Fernando et
al., 1994), and it has been suggested that the yield of samples
in which SPF can be estimated may in fact be increased by
using FNAB (Remvikos et al., 1989).
DNA flow cytometric estimation of SPF remains an
important technique, however not all laboratories have access
to such high-technology equipment. In addition, SPF can
only be estimated in a proportion of tumours (approximately
75-85%) (Camplejohn et al., 1994) for a number of reasons,
including low cellularity of the sample, obstructing cell
debris, and overlapping aneuploid peaks. Immunohistochem-
ical analysis with Ki-67 or MIB-1 allows estimation of
proliferation index in virtually 100% of specimens. Unlike
flow cytometry, it also offers simultaneous evaluation of
tumour histology. The principal drawback of the Ki-67
antibody is that the antigen does not survive routine
histological fixation and its application is restricted to fresh
tissue. MIB-1 immunostaining, however, combines strong
immunoreactivity with optimal preservation of morphology
and can be easily applied to routinely fixed and wax-
embedded specimens.
In summary, we have shown that MIB-1 reactivity
correlates with SPF, an established proliferation assay. It
is a technique that can accurately measure cell proliferation
in breast carcinomas using simple, widely available
technology that is neither time-consuming, expensive, nor
labour intensive. Its use thus provides the opportunity to
perform large-scale retrospective analyses of archival
material.
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